Compare AbbVie Inc (ABBV) vs HubSpot Inc (HUBS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs HubSpot Inc — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while HubSpot Inc trades at $198.17 (market cap $10.50B). The key difference: AbbVie Inc is far larger — about 42.8× HubSpot Inc's market cap, and AbbVie Inc pays a 2.72% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals.
| ABBV | HUBS | |
|---|---|---|
Market Cap | $449.91B | $10.50B |
Sector | Health | Technology |
52-Week High | $261.07 | $560.90 |
52-Week Low | $184.85 | $170.39 |
Enterprise Value | $513.38B | $9.06B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
HUBS trades at $205.23, up 6.82% in the last session, reflecting strong momentum. The stock shows bullish technical signals with support at $188 and resistance at $208. Recent earnings beats and 23% revenue growth in Q1 2026 highlight robust execution. Analyst consensus is overwhelmingly bullish with an 80.85% buy rating and a $273.53 price target, suggesting significant upside from current levels.
Outlook remains positive driven by AI integration and customer growth, but high P/E of 102.02 poses valuation risk. Competition from Salesforce and SaaS sector volatility are key concerns. Net income margin improvement to 3.04% in 2025 signals profitability traction, yet investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
